IDL Diagnostics AB (publ) (STO:IDLDX)

Market Cap	135.91M
Revenue (ttm)	59.94M
Net Income (ttm)	-44.27M
Shares Out	230.36M
EPS (ttm)	-0.19
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	31,070
Average Volume	217,217
Open	0.5920
Previous Close	0.5900
Day's Range	0.5500 - 0.5920
52-Week Range	0.3460 - 0.6600
Beta	1.21
RSI	54.25
Earnings Date	Aug 21, 2025

About IDL Diagnostics AB

AroCell AB (publ), a vitro diagnostics company, manufactures and sells IVD tests for oncological and bacterial diseases in Sweden. It offers UBC Rapid, a point-of-care test for diagnosis and monitoring of bladder cancer; AroCell TK 210 ELISA, a biomarker for tumor cell; and TUBEX TF, a vitro diagnostic test for detection of acute typhoid fever. The company was formerly known as Xi Bao Research AB and changed its name to AroCell AB (publ) in 2006. AroCell AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2000
• Employees: 20
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: IDLDX

Financial Performance

In 2024, IDL Diagnostics AB's revenue was 57.44 million, an increase of 33.45% compared to the previous year's 43.04 million. Losses were -42.45 million, -28.41% less than in 2023.